{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-113091","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2024-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.676237+00:00","generated_at":"2026-05-30T19:24:59.651400+00:00","sec_items":["1.01","2.01","3.02","5.02","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galecto acquires global rights to BRM-1420 dual ENL-YEATS/FLT3 inhibitor for AML","bullets":["Galecto issued 62,594 common shares and 160.562 Series A convertible preferred shares (convertible into 160,562 common) to Bridge Medicines.","BRM-1420 is a novel dual ENL-YEATS and FLT3 inhibitor targeting multiple genetic subsets of acute myeloid leukemia (AML).","Carl Goldfischer, Galecto's Chairman, also serves as Executive Chairman of Bridge Medicines (related-party transaction).","Pro forma impact: cash reduced by $2.68M; total consideration valued at stock issuance; assumes liabilities.","Stockholder approval required for conversion of preferred shares; Bridge Medicines restricted from selling shares for 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-113091","json":"https://secwatch.observer/filing/0000950170-24-113091.json","markdown":"https://secwatch.observer/filing/0000950170-24-113091.md","text":"https://secwatch.observer/filing/0000950170-24-113091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000095017024113091/0000950170-24-113091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000095017024113091/glto-20241007.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T19:24:59.651400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}